The AmpliSeq for Illumina Comprehensive Cancer Panel provides a targeted resequencing solution for analyzing somatic mutations across 409 genes with known associations to cancer. Key features include:
The Comprehensive Cancer Panel is part of an integrated workflow that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS) next-generation sequencing (NGS) technology, and automated analysis.
This panel detects variants within multiple cancer types, including lung, colon, breast, ovarian, melanoma, and prostate malignancies. The ready-to-use panel saves you the time and effort of identifying targets, designing primers, and optimizing panels.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| NextSeq 550 System | Samples per run: mid output: 4, high output: 12 (assumes minimum coverage of 500×) | 2 × 150 bp |
| AmpliSeq for Illumina Comprehensive Cancer Panel | AmpliSeq for Illumina Cancer Hotspot Panel v2 |
|---|
Automated Solutions for AmpliSeq for Illumina Sequencing Panels
Application Note | HTML
Sample Identification with the AmpliSeq for Illumina Sample ID Panel Application Note
Application Note | HTML
AmpliSeq for Illumina Comprehensive Cancer Panel Data Sheet
Data Sheet | HTML
AmpliSeq for Illumina Comprehensive Cancer Panel Gene List
product_file | EXCEL < 1 MB
NextSeq 550 amplicon sequencing solution
Application Note | PDF < 1 MB
Custom Protocol Selector
Generates customized, end-to-end instructions
Targeted DNA and RNA research panel investigating variants across 161 genes associated with a range of cancer types.
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
Targeted research panel investigating hotspot regions of 50 genes with known associations to cancer.
Targeted panel that measures expression levels of >20,000 human RefSeq genes.
MiSeq sequencing reagents in pre-filled, ready-to-use cartridges. Micro and nano formats are available for low output applications.
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
